Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces actions to strengthen its competitive position. These actions are expected to deliver structural cost savings of up to EUR 100 million per year by 2010. In addition, DSM is also taking a number of measures to address the current more difficult market conditions. These market conditions together with the decision to currently prioritize cash over short term profitability are resulting in a revised full year guidance for 2008 operating profit of above EUR 900 million, around 10% higher compared to 2007 and a record result for the company.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that a definitive agreement has been signed to sell its Solutech business to Lydall, Inc., the United States-based specialty engineered products manufacturer. Financial details of the transaction will not be disclosed.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Nutritional Products has opened its third premix plant in China. The new facility allows DSM to serve a larger geographical area in China. This enables the company to capitalize on opportunities that arise from the rapidly growing animal nutrition & health industry in one of the key growth countries for DSM.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces today that it has reached an agreement with the management of DSM Deretil on a management buy-out. DSM Deretil is a business unit of DSM Anti-Infectives. Financial details will not be disclosed.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces today that Ad Overbeek, Global Science Manager DSM NeoResins+, has been selected by The Federation of Societies for Coatings Technology (FSCT) to deliver the 2009 Joseph J. Mattiello Memorial Lecture.

Continued strong organic sales growth (12%), driven by pricing power. Sustained strong profitability in Nutrition. Accelerating economic downturn increasingly visible in Materials Sciences. EBIT from continuing operations up 27% to EUR 267 million; EPS up 41%. 2008 operating profit expected to be around EUR 1,000 million.

DSM and the Dutch Olympic Committee/Dutch Sports Federation (NOC*NSF) will continue to be ‘Partners in Sports’ in the run-up to the London 2012 Olympics. The partners have today signed an agreement to this effect at the Papendal Dutch National Sports Centre. As innovation partner of NOC*NSF, DSM is supporting the Dutch Olympic team with innovations in the field of nutrition and materials in order to help the team achieve top performances.

Royal DSM N.V., the global Life Sciences and Materials Sciences company today announced the execution of a multimillion dollar cooperative funding agreement with the US Department of Energy to underwrite a portion of research and development costs aimed at enabling “second generation” biofuels from non-food feedstocks.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and the United Nations World Food Programme (WFP) announce that the 2008 ICIS Innovation Awards for Best Business Innovation has been awarded to DSM Nutritional Products and WFP for the MixMe™ micronutrient powder.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces that it has made an investment in the new business incubator in the field of medical devices Accelerated Technologies II, L.P. (ATP). The investment further strengthens DSM’s position in the biomedical materials market, one of the Emerging Business Areas defined in its Vision 2010 – Building on Strengths strategy. Financial details will not be disclosed.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Anti-Infectives has decided to close its site in Strängnäs, Sweden. The site mainly produces clavulanic acid. Total cost of closure will be slightly above EUR 10 million (after tax) and will be reported as an exceptional item in Q4.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that the renowned scientific journal “Nature Biotechnology” is publishing a paper in its October 2008 issue on a breakthrough analysis of the DNA sequence of the fungus Penicillium chrysogenum. The paper is the result of a major research project initiated by DSM in which seven international research groups participated.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces that it has made an equity investment in The Compliers Group International B.V. (TCG). The Netherlands-based company focuses on the development of smart pharmaceutical packaging solutions that contain microchips which enable the monitoring of a patient’s therapy compliance. Financial details of the investment will not be disclosed.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, will update analysts and investors at its annual conference in Vaalsbroek on 25 and 26 September 2008 on the progress made in its Vision 2010 strategy. DSM is also updating its 2008 EBIT guidance today, from EUR 970 million, with potential upside, to EUR 1,025-1,075 million on the back of continued strength in some of DSM’s businesses, particularly DSM Agro.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in The Netherlands, today announces that the second polymerization plant for Stanyl® polyamide 46 on the Chemelot site in Geleen (Netherlands) has opened. The new plant doubles DSM’s worldwide production capacity for this high-performance plastic, supporting expected continuous strong growth in the coming years based on the leading position of Stanyl® in electronics and the growing usage in automotive applications due to higher demand for metal replacement. DSM has invested several tens of millions of euros in the new plant.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in The Netherlands, today announces a major capacity expansion for its innovative picture glass ®claryl. Within a year after its launch, market demand for this innovative product has risen so quickly that DSM decided to build an additional oven at its manufacturing facility in Geleen, the Netherlands, increasing production capacity by 50%.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Biomedical and Caliber Therapeutics, Inc. will partner on the development of a novel drug delivery balloon catheter that can be used to treat vascular diseases such as atherosclerosis. This cooperation is another step for DSM to leverage its competences in Materials Sciences into Life Sciences applications.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in The Netherlands, has successfully increased its outstanding EUR 300 million 4.00% bond due 2015 by EUR 200 million. The increase, triggered by interest of investors, has been placed to institutional investors across Europe.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces the inauguration of its new polymer plant in Jiangyin (Jiangsu province, China).

Royal DSM N.V., the global Life Sciences and Materials Sciences Company headquartered in the Netherlands, today announces the closure of its citric acid manufacturing plant in Wuxi (China) by Q1 2009.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces that it has acquired an equity stake of 29.3% in Provexis plc, an AIM listed company that develops and licenses ingredients for the functional food, medical food and dietary supplement market. The investment makes DSM the largest shareholder of Provexis.

DSM becomes official sponsor of Dutch swimmer Marleen Veldhuis. Broad range of innovations for Dutch Olympic Team. Innovations in the pipeline.

Royal DSM N.V. has appointed Mrs A.M. (Margo) Vliegenthart as member of the Supervisory Board of DSM Nederland B.V. (“DSM Netherlands”) with effect from 1 August 2008. Mrs Vliegenthart fills the vacancy caused by the untimely death of Mr M.A.M. (Thijs) Wöltgens earlier this year.

Very strong Q2 result based on 17% organic sales growth. Changing dynamics in vitamin business drive significantly higher profitability in Life Sciences. Materials Sciences performing well against difficult economic background. EBIT from continuing operations up 19% to EUR 276 million. Earnings per share 34% higher. Guidance raised: 2008 EBIT from continuing operations expected to be around EUR 970 million, with potential upside. Execution of Vision 2010 strategy fully on track.

Olympic field hockey players and footballers use cooling bath for quicker recovery.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces the acquisition of the business and substantially all of the assets of Valley Research Inc. of South Bend Indiana, United States. Through this acquisition, DSM further reinforces its leading global position in food enzymes.

Royal DSM N.V. has repurchased 534,797 of its own shares in the period from 3 July 2008 up to and including 8 July 2008 at an average price of EUR 35.90. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today reports that an interruption in production that occurred at DSM Agro last month will take longer to end than originally anticipated. In view of the current positive business climate the outlook will not be lowered due to this event.

Royal DSM N.V. has repurchased 860,787 of its own shares in the period from 26 June 2008 up to and including 2 July 2008 at an average price of EUR 37.22. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Craig J. Hawker, Professor of Chemistry, Biochemistry and Materials and Director of the Materials Research Laboratory at the University of California, Santa Barbara, USA, has been awarded the DSM Performance Materials Award 2008 in recognition of his exceptional contributions to the advancement of the materials sciences.

Royal DSM N.V. has repurchased 749,000 of its own shares in the period from 19 June 2008 up to and including 25 June 2008 at an average price of EUR 38.21. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that its Scotland based vitamin manufacturing facility has been awarded the Carbon Trust Standard certification.

Royal DSM N.V. has repurchased 896,247 of its own shares in the period from 12 June 2008 up to and including 18 June 2008 at an average price of EUR 39.91. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

German researcher Andreas Walther has won the first prize in the DSM Science & Technology Awards (South) 2008.

DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announce another breakthrough in the production of IgG antibodies using PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD™ technology, a record yield of over 27 grams per liter has been achieved. In March 2008 a yield of 15 grams per liter was reported.

Royal DSM N.V. has repurchased 783,673 of its own shares in the period from 5 June 2008 up to and including 11 June 2008 at an average price of EUR 38.96. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V. has repurchased 769,914 of its own shares in the period from 29 May 2008 up to and including 4 June 2008 at an average price of EUR 39.17. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Belgian researcher Maarten Roeffaers of the Catholic University of Leuven has won the first prize in the DSM Science & Technology Awards (North) 2008.

Royal DSM N.V. has repurchased 560,166 of its own shares in the period from 22 May 2008 up to and including 28 May 2008 at an average price of EUR 37.40. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that it has closed the acquisition of The Polymer Technology Group, Inc. (PTG) of Berkeley (California, United States), a market leader in the field of biomedical polymers.

Royal DSM N.V. has repurchased 671,891 of its own shares in the period from 15 May 2008 up to and including 21 May 2008 at an average price of EUR 36.81. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V. has repurchased 490,192 of its own shares in the period from 8 May 2008 up to and including 14 May 2008 at an average price of EUR 35.59. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V. has repurchased 298,333 of its own shares in the period from 5 May 2008 up to and including 7 May 2008 at an average price of EUR 35.46. This is in accordance with the second phase of the share buyback program, announced on 5 May 2008.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces that the company will today, 5 May 2008, start the second phase of the share buy-back program of EUR 750 million announced on 27 September 2007.

Organic sales growth 14% due to strong business positions and favorable market conditions. EBIT from continuing operations up 22% despite lower US dollar and higher feedstock prices. Earnings per share up 42%. Execution of Vision 2010 strategy fully on track. Resumption of share buy-back program for next EUR 250 million as of 5 May. Outlook: 2008 EBIT expected to be EUR 870 million +/- 5%.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces an agreement to acquire The Polymer Technology Group, Inc. (PTG) of Berkeley (California, United States).

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announced the opening of the market development plant for PA4T, the new polymer for use in electronics and other applications. The plant is operational as of today.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces plans for a substantial capital expenditure program, expected to involve up to USD 450 million.

Royal DSM N.V. announces the following management appointments: Jos Goessens (1951), at present Business Group Director DSM Engineering Plastics, has been appointed Director Strategic Projects, reporting to the Managing Board. Roelof Westerbeek (1963) has been appointed Business Group Director DSM Engineering Plastics with effect from 1 October 2008.

Royal DSM N.V. today provides the investment community with comparative figures for 2007 that reflect the company’s new cluster structure as of 1 January 2008. The new structure was announced in September 2007 and is a result of the acceleration of DSM’s strategy Vision 2010 – Building on Strengths.

The DSM Annual General Meeting of Shareholders on 26 March 2008 passed a resolution to declare a dividend for 2007 of EUR 1.20 per ordinary share of EUR 1.50 par value. An interim dividend of EUR 0.33 per ordinary share having been paid on 22 August 2007, the final dividend for 2007 will amount to EUR 0.87 per ordinary share.

Royal DSM N.V. today held its Annual General Meeting of Shareholders.

At the Annual General Meeting being held later today, DSM will provide a trading update for 2008.

Royal DSM N.V. is today presenting its fifth annual sustainability report: the Triple P (People, Planet, Profit) Report 2007 entitled Embracing the Future.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has made an equity investment in the Dutch company IQ Therapeutics B.V.

DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announced that it has participated in a USD 20 million financing round in Tianjin Green Bio-Science Co., Ltd (China).

DSM, the innovative partner in sports of the Dutch Olympic Committee (NOC*NSF), is presenting a number of major innovations for the sport of sailing

The Dutch Ministers Cramer (Housing, Spatial Planning and the Environment) and Eurlings (Transport, Public Works and Water Management) and DSM today announce that they have reached an agreement in principle on the termination of ammonia transport by rail between Geleen and IJmuiden.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, has reached an agreement in principle with Arsenal Capital Partners (United States) on the sale of DSM Special Products BV.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, has received a grant from the US Department of Energy for a technical consortium on an innovative biotechnological approach of bioproducts and biofuels.

DSM proposes appointing Mrs Louise Gunning-Schepers as a member of its Supervisory Board.

Strong Q4 results based on 10% organic sales growth. Operating profit for 2007 of EUR 823 million in line with expectations. Net profit before exceptional items at EUR 558 million, better than last year; EPS 8% higher. Proposed dividend EUR 1.20 per ordinary share (+20%). Outlook: Operating profit before exceptional items in 2008 expected to approach level achieved in 2007.

Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and the French starch and starch-derivatives company ROQUETTE have joined forces to implement and commercialize the fermentative production of biorenewable succinic acid, which – amongst other applications - opens the possibility to produce bio-based performance materials.

Royal DSM N.V., the leading Life Sciences and Materials Sciences company from the Netherlands, today announces the acquisition of the US-based company Soluol, a developer, producer and marketer of high performance urethane resins which are used in a wide range of applications, with annual sales of USD 20 million.

Royal DSM N.V., the leading Life Sciences and Materials Sciences company from the Netherlands, today announces that it will invest nearly EUR 15 million in the construction of a new plant for the production of wet polyesters and other specialty resins in Meppen, Germany.